Vosoritide - BioMarin Pharmaceutical

Drug Profile

Vosoritide - BioMarin Pharmaceutical

Alternative Names: BMN-111; Modified C-natriuretic peptide; Modified recombinant human C-type natriuretic peptide; ProCNP38

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioMarin Pharmaceutical
  • Class Cyclic peptides; Natriuretic agents; Natriuretic peptides; Recombinant proteins
  • Mechanism of Action C-type natriuretic peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Achondroplasia

Most Recent Events

  • 12 Dec 2017 BioMarin initiates enrolment in a long-term extension phase III trial for Achondroplasia (In adolescents, In children) in Australia (NCT03424018)
  • 26 Oct 2017 BioMarin Pharmaceutical plans a phase II trial for Achondroplasia (In children, In infants, In neonates) in the first half of 2018
  • 18 Oct 2017 Efficacy data from a phase II trial in Achondroplasia released by BioMarin
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top